JP2007504128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007504128A5 JP2007504128A5 JP2006524603A JP2006524603A JP2007504128A5 JP 2007504128 A5 JP2007504128 A5 JP 2007504128A5 JP 2006524603 A JP2006524603 A JP 2006524603A JP 2006524603 A JP2006524603 A JP 2006524603A JP 2007504128 A5 JP2007504128 A5 JP 2007504128A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- compound
- independently selected
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 3
- 200000000018 inflammatory disease Diseases 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 229910052760 oxygen Inorganic materials 0.000 claims 11
- 229910052717 sulfur Inorganic materials 0.000 claims 11
- 125000005842 heteroatoms Chemical group 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 239000011780 sodium chloride Substances 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 102000016799 Leukocyte Elastase Human genes 0.000 claims 2
- 108010028275 Leukocyte Elastase Proteins 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003287 optical Effects 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 1
- 201000004624 dermatitis Diseases 0.000 description 3
- 210000000056 organs Anatomy 0.000 description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003230 Arteritis Diseases 0.000 description 1
- 206010003246 Arthritis Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010003816 Autoimmune disease Diseases 0.000 description 1
- 210000003719 B-Lymphocytes Anatomy 0.000 description 1
- 210000004204 Blood Vessels Anatomy 0.000 description 1
- 210000001185 Bone Marrow Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000016795 Cola Nutrition 0.000 description 1
- 240000001644 Cola acuminata Species 0.000 description 1
- 235000011824 Cola pachycarpa Nutrition 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000004275 Demyelinating Disease Diseases 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010064147 Gastrointestinal inflammation Diseases 0.000 description 1
- 208000007565 Gingivitis Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 208000003393 Mammary Paget's Disease Diseases 0.000 description 1
- 206010027476 Metastasis Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000011829 Ow cola Nutrition 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 206010040943 Skin ulcer Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- 201000001320 atherosclerosis Diseases 0.000 description 1
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 1
- 201000010816 bone resorption disease Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 230000000112 colonic Effects 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 231100000406 dermatitis Toxicity 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 201000005569 gout Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- 201000004044 liver cirrhosis Diseases 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 201000008838 periodontal disease Diseases 0.000 description 1
- 230000002980 postoperative Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0302323A SE0302323D0 (sv) | 2003-08-28 | 2003-08-28 | Novel compounds |
| PCT/SE2004/001226 WO2005021509A1 (en) | 2003-08-28 | 2004-08-25 | Quinoline derivatives as neutrophil elastase inhibitors and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504128A JP2007504128A (ja) | 2007-03-01 |
| JP2007504128A5 true JP2007504128A5 (US07846941-20101207-C00217.png) | 2007-09-06 |
Family
ID=28673217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006524603A Pending JP2007504128A (ja) | 2003-08-28 | 2004-08-25 | 好中球エラスターゼ阻害剤としてのキノリン誘導体およびその使用 |
Country Status (6)
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200500341A (en) * | 2002-11-12 | 2005-01-01 | Astrazeneca Ab | Novel compounds |
| SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
| SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| WO2007017670A1 (en) | 2005-08-08 | 2007-02-15 | Argenta Discovery Ltd. | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0605469D0 (en) * | 2006-03-17 | 2006-04-26 | Argenta Discovery Ltd | Multimers of heterocyclic compounds and their use |
| TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
| TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
| JP2010510202A (ja) | 2006-11-17 | 2010-04-02 | ファイザー株式会社 | 置換ビシクロカルボキシアミド化合物 |
| WO2008113006A1 (en) * | 2007-03-14 | 2008-09-18 | Xenon Pharmaceuticals Inc. | Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions |
| WO2009061271A1 (en) | 2007-11-06 | 2009-05-14 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
| TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
| WO2011039528A1 (en) * | 2009-10-02 | 2011-04-07 | Astrazeneca Ab | 2-pyridone compounds used as inhibitors of neutrophil elastase |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| CN103058927B (zh) * | 2011-10-21 | 2015-04-22 | 华国媛 | 一种喹啉衍生物及其应用 |
| AU2012331289B2 (en) | 2011-11-04 | 2017-07-13 | F. Hoffmann-La Roche Ag | New aryl-quinoline derivatives |
| US9775843B2 (en) | 2012-10-11 | 2017-10-03 | Grünenthal GmbH | Treatment and/or prophylaxis of TSPO mediated diseases and/or disorders |
| CN105726538A (zh) * | 2016-03-28 | 2016-07-06 | 张雪燕 | 一种抗肺纤维化的药物组合物及其应用 |
| CN111683976B (zh) | 2018-02-05 | 2022-11-18 | 生物辐射实验室股份有限公司 | 具有阴离子交换-疏水混合模式配体的色谱树脂 |
| BR112022004861A2 (pt) | 2019-09-17 | 2022-06-07 | Univ Duke | Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro |
| IL297211A (en) | 2020-04-16 | 2022-12-01 | Mereo Biopharma 4 Ltd | Methods involving the neutrophil elastase inhibitor albalstat for the treatment of respiratory disease mediated by alpha-1 antitrypsin deficiency |
| TW202325294A (zh) | 2021-10-20 | 2023-07-01 | 英商梅瑞奧生物製藥４有限公司 | 用於治療纖維化之嗜中性球彈性蛋白酶抑制劑 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2706977A1 (de) * | 1977-02-18 | 1978-08-24 | Hoechst Ag | Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung |
| ZA794209B (en) * | 1978-08-15 | 1980-07-30 | Fisons Ltd | Pharmaceutically active heterocyclic compounds |
| EP0008864A1 (en) * | 1978-08-15 | 1980-03-19 | FISONS plc | Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them |
| JPH02152966A (ja) * | 1988-12-05 | 1990-06-12 | Otsuka Pharmaceut Co Ltd | ４−ヒドロキシカルボスチリル誘導体 |
| JP3122671B2 (ja) * | 1990-05-23 | 2001-01-09 | 協和醗酵工業株式会社 | 複素環式化合物 |
| US5521179A (en) * | 1991-04-18 | 1996-05-28 | Zeneca Limited | Heterocyclic amides |
| US5441960A (en) * | 1992-04-16 | 1995-08-15 | Zeneca Limited | 1-pyrimidinylacetamide human leukocyte elastate inhibitors |
| JP2001192398A (ja) * | 1996-12-06 | 2001-07-17 | Cortech Inc | セリンプロテアーゼ阻害剤 |
| JPH1171351A (ja) * | 1997-08-29 | 1999-03-16 | Ss Pharmaceut Co Ltd | 置換キノロン誘導体及びこれを含有する医薬 |
| AU736232B2 (en) * | 1997-12-03 | 2001-07-26 | Nihon Nohyaku Co., Ltd. | 1,2-dihydro-2-oxoquinoline derivatives |
| EP2177520A1 (en) * | 2000-06-12 | 2010-04-21 | Eisai R&D Management Co., Ltd. | 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors |
| ES2330719T3 (es) * | 2000-12-28 | 2009-12-15 | SHIONOGI & CO., LTD. | Derivados de 2-piridona con afinidad para el receptor cannabinoide de tipo 2. |
| SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
-
2003
- 2003-08-28 SE SE0302323A patent/SE0302323D0/xx unknown
-
2004
- 2004-08-25 WO PCT/SE2004/001226 patent/WO2005021509A1/en active Application Filing
- 2004-08-25 EP EP04775332A patent/EP1660452A1/en not_active Withdrawn
- 2004-08-25 US US10/569,571 patent/US20070010551A1/en not_active Abandoned
- 2004-08-25 CN CNB2004800249875A patent/CN100427469C/zh not_active Expired - Fee Related
- 2004-08-25 JP JP2006524603A patent/JP2007504128A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504128A5 (US07846941-20101207-C00217.png) | ||
| US10195186B2 (en) | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | |
| CN1178658C (zh) | 合成环加氧酶-2抑制剂的方法 | |
| US20040259842A1 (en) | Intracellular calcuim concentration increase inhibitors | |
| CN110269856A (zh) | 多取代芳族化合物作为凝血酶的抑制剂 | |
| WO2006064757A1 (ja) | アミノカルボン酸誘導体およびその医薬用途 | |
| JP2009543836A (ja) | インドール化合物 | |
| JP2006516137A (ja) | Ｃｂ−１リガンドとしての４，５−ジアリールチアゾール誘導体 | |
| JP7089596B2 (ja) | 肝がんの治療及び予防のための７位置換スルホンイミドイルプリノン化合物及び誘導体 | |
| WO2006080323A1 (ja) | ヘテロ６員環化合物及びその用途 | |
| JP2015534554A (ja) | アルキル，フルオロアルキル−１，４−ベンゾジアゼピノン化合物 | |
| JP2000505063A (ja) | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 | |
| JPS63152388A (ja) | 新規なセフェム化合物 | |
| JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
| EP4143193A1 (en) | Imidazopyrimidines as modulators of il-17 | |
| CN111479814A (zh) | 作为h-pgds抑制剂的稠合的吡啶 | |
| BE898383A (fr) | Pyrazoloquinoleines substituees particulieres, procede pour leur preparation, preparations pharmaceutiques contenant ces composes et leur application therapeutique. | |
| JP7312745B2 (ja) | アゼチジン誘導体及びそのプロドラッグ | |
| CN114364665A (zh) | 调节白介素的前药 | |
| CA2080340A1 (fr) | Derives de l'oxazole, leur preparation et les compositions pharmaceutiques qui les contiennent | |
| JPS6058747B2 (ja) | アミノ化合物の製法 | |
| JP7025542B2 (ja) | Ｔｇｆ－ベータ阻害剤としてのオキサジアゾール及びチアジアゾール | |
| CH646976A5 (de) | 7-alpha-methoxycephalosporine und verfahren zur herstellung derselben. | |
| JP3670309B2 (ja) | 二環性複素環化合物 | |
| JPH06172287A (ja) | アミノカルボン酸誘導体及び該化合物を含有する医薬組成物 |